Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University Hospital, Rouen
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
University Hospital, Rouen
University Hospital, Rouen
University of Pittsburgh
M.D. Anderson Cancer Center
University of Texas Southwestern Medical Center
M.D. Anderson Cancer Center
University Hospital, Rouen
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Texas Southwestern Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
University Hospital, Rouen
M.D. Anderson Cancer Center
Novartis
M.D. Anderson Cancer Center
Novartis
University of Cincinnati
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Eli Lilly and Company
Teclison Ltd.
Curis, Inc.
Memorial Sloan Kettering Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
Pfizer
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
SkinJect, Inc.
Miltenyi Biomedicine GmbH
National Cancer Institute (NCI)
Massachusetts General Hospital
Incyte Corporation
M.D. Anderson Cancer Center
Shanghai Junshi Bioscience Co., Ltd.